Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Breast Cancer

  Free Subscription


Articles published in Eur J Cancer

Retrieve available abstracts of 82 articles:
HTML format



Single Articles


    November 2022
  1. BRAVACCINI S, Puccetti M, Maltoni R
    Re: "Evolution of low HER2 expression between early and advanced-stage breast cancer".
    Eur J Cancer. 2022 Nov 13. pii: S0959-8049(22)00801.
    PubMed    


  2. TARANTINO P, Nicolo E, Curigliano G
    Response to letter entitled: Re: "Evolution of low HER2 expression between early and advanced-stage breast cancer".
    Eur J Cancer. 2022 Nov 9. pii: S0959-8049(22)00802.
    PubMed    


    October 2022
  3. LOIBL S, Loirat D, Tolaney SM, Punie K, et al
    Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer.
    Eur J Cancer. 2022;178:23-33.
    PubMed     Abstract available


  4. VAN DAM P, Tomatis M, Ponti A, Marotti L, et al
    The impact of the SARS-COV-2 pandemic on the quality of breast cancer care in EUSOMA-certified breast centres.
    Eur J Cancer. 2022;177:72-79.
    PubMed     Abstract available


  5. GHANNAM Y, Di Meglio A, Sarrade T, Jacquet A, et al
    Impact of radiation therapy on fatigue at 1 year in breast cancer survivors in the prospective multicentre CANcer TOxicity cohort.
    Eur J Cancer. 2022;177:143-153.
    PubMed     Abstract available


  6. SWAIN SM, Tan AR, Gianni L, Kuemmel S, et al
    Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer.
    Eur J Cancer. 2022;178:70-81.
    PubMed     Abstract available


  7. HUANG M, O'Shaughnessy J, Haiderali A, Pan W, et al
    Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1.
    Eur J Cancer. 2022;177:45-52.
    PubMed     Abstract available


  8. TARANTINO P, Niman SM, Erick TK, Priedigkeit N, et al
    HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications.
    Eur J Cancer. 2022;174:277-286.
    PubMed     Abstract available


  9. VILLACAMPA G, Falato C, Pare L, Hernando C, et al
    Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial.
    Eur J Cancer. 2022;174:232-242.
    PubMed     Abstract available


  10. M A, S C, J F, C L, et al
    Incidence and Outcome of Breast Sarcomas in England (2013-2018): An analysis from the National Cancer Registration and Analysis Service.
    Eur J Cancer. 2022;174:48-56.
    PubMed     Abstract available


  11. HOUVENAEGHEL G, de Nonneville A, Cohen M, Classe JM, et al
    Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective study.
    Eur J Cancer. 2022;176:58-69.
    PubMed     Abstract available


    September 2022
  12. KANG S, Lee SH, Lee HJ, Jeong H, et al
    Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy.
    Eur J Cancer. 2022;176:30-40.
    PubMed     Abstract available


  13. JIANG H, Ouyang Q, Yin Y, Tong Z, et al
    Proxalutamide in patients with AR-positive metastatic breast cancer: Results from an open-label multicentre phase Ib study and biomarker analysis.
    Eur J Cancer. 2022;176:1-12.
    PubMed     Abstract available


  14. PFOB A, Sidey-Gibbons C, Barr RG, Duda V, et al
    Intelligent multi-modal shear wave elastography to reduce unnecessary biopsies in breast cancer diagnosis (INSPiRED 002): a retrospective, international, multicentre analysis.
    Eur J Cancer. 2022;177:1-14.
    PubMed     Abstract available


  15. XU B, Hu X, Li W, Sun T, et al
    Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4.
    Eur J Cancer. 2022;175:236-245.
    PubMed     Abstract available


  16. BAEZ-NAVARRO X, Salgado R, Denkert C, Lennerz JK, et al
    Selecting patients with HER2-low breast cancer: Getting out of the tangle.
    Eur J Cancer. 2022;175:187-192.
    PubMed     Abstract available


  17. VLIEK SB, Hilbers FS, Jager A, Retel VP, et al
    Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancer.
    Eur J Cancer. 2022;175:169-179.
    PubMed     Abstract available


  18. KREGTING LM, Olthof EMG, Breekveldt ECH, Aitken CA, et al
    Concurrent participation in breast, cervical, and colorectal cancer screening in the Netherlands.
    Eur J Cancer. 2022;175:180-186.
    PubMed     Abstract available


  19. GROOTES I, Keeman R, Blows FM, Milne RL, et al
    Incorporating progesterone receptor expression into the PREDICT breast prognostic model.
    Eur J Cancer. 2022;173:178-193.
    PubMed     Abstract available


  20. DE BOER AZ, Bastiaannet E, Schetelig J, de Glas NA, et al
    Breast cancer mortality of older patients with and without recurrence analysed by novel multi-state models.
    Eur J Cancer. 2022;174:212-220.
    PubMed     Abstract available


  21. REINERT T, Goncalves AC, de Resende CAA, Barrios CH, et al
    Implications of the PEARL trial from the low- to middle-income countries' perspectives.
    Eur J Cancer. 2022;173:30-32.
    PubMed    


    August 2022
  22. CHEN SY, Sun GY, Tang Y, Jing H, et al
    Timing of postmastectomy radiotherapy following adjuvant chemotherapy for high-risk breast cancer: A post hoc analysis of a randomised controlled clinical trial.
    Eur J Cancer. 2022;174:153-164.
    PubMed     Abstract available


  23. GOLDRAT O, De Cooman M, Mailliez A, Delbaere A, et al
    Efficacy and safety of controlled ovarian hyperstimulation with or without letrozole for fertility preservation in breast cancer patients: A multicenter retrospective study.
    Eur J Cancer. 2022;174:134-141.
    PubMed     Abstract available


  24. KARSTEN MM, Roehle R, Albers S, Pross T, et al
    Corrigendum to 'Real-world reference scores for EORTC QLQ-C30 and EORTC QLQ-BR23 in early breast cancer patients [European Journal of Cancer 163 (2022) 128-139].
    Eur J Cancer. 2022 Aug 12. pii: S0959-8049(22)00403.
    PubMed    


  25. GIORGI ROSSI P
    What a woman needs to know about overdiagnosis to decide about breast cancer screening.
    Eur J Cancer. 2022 Aug 5. pii: S0959-8049(22)00408.
    PubMed    


    July 2022
  26. ANDERSON RA, Lambertini M, Hall PS, Wallace WH, et al
    Survival after breast cancer in women with a subsequent live birth: Influence of age at diagnosis and interval to subsequent pregnancy.
    Eur J Cancer. 2022;173:113-122.
    PubMed     Abstract available


  27. LEONE JP, Graham N, Tolaney SM, Leone BA, et al
    Estimating long-term mortality in women with hormone receptor-positive breast cancer: The 'ESTIMATE' tool.
    Eur J Cancer. 2022;173:20-29.
    PubMed     Abstract available


  28. ALMSTEDT K, Heimes AS, Kappenberg F, Battista MJ, et al
    Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer.
    Eur J Cancer. 2022;173:10-19.
    PubMed     Abstract available


  29. DING L, Poelhekken K, Greuter MJW, Truyen I, et al
    Overdiagnosis of invasive breast cancer in population-based breast cancer screening: A short- and long-term perspective.
    Eur J Cancer. 2022;173:1-9.
    PubMed     Abstract available


  30. BUDDE A, Baust K, Weinhold L, Bernstein M, et al
    Linking EORTC QLQ-C-30 and PedsQL/PEDQOL physical functioning scores in patients with osteosarcoma.
    Eur J Cancer. 2022;170:209-235.
    PubMed     Abstract available


    June 2022
  31. BATTISTI NML, De Glas N, Soto-Perez-de-Celis E, Liposits G, et al
    Chemotherapy and gene expression profiling in older early luminal breast cancer patients: An International Society of Geriatric Oncology systematic review.
    Eur J Cancer. 2022;172:158-170.
    PubMed     Abstract available


  32. ESTEVES F, Xavier JM, Ford AM, Rocha C, et al
    Germline allelic expression of genes at 17q22 locus associates with risk of breast cancer.
    Eur J Cancer. 2022;172:146-157.
    PubMed     Abstract available


  33. BATTISTI NML, Smith IE
    Preventing late recurrence in hormone receptor-positive early breast cancer: a review.
    Eur J Cancer. 2022;172:53-64.
    PubMed     Abstract available


  34. YAMADA A, Hayashi N, Kumamaru H, Nagahashi M, et al
    Prognostic impact of postoperative radiotherapy in patients with breast cancer and with pT1-2 and 1-3 lymph node metastases: A retrospective cohort study based on the Japanese Breast Cancer Registry.
    Eur J Cancer. 2022;172:31-40.
    PubMed     Abstract available


  35. OZAKI Y, Tsurutani J, Mukohara T, Iwasa T, et al
    Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B).
    Eur J Cancer. 2022;171:193-202.
    PubMed     Abstract available


  36. MULLER V, Hein A, Hartkopf AD, Fasching PA, et al
    Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry.
    Eur J Cancer. 2022;172:13-21.
    PubMed     Abstract available


  37. ZHANG J, Gao HF, Yang C, Zhu T, et al
    Prevention of taxane-associated acute pain syndrome with etoricoxib for patients with breast cancer: A phase II randomised trial.
    Eur J Cancer. 2022;171:150-160.
    PubMed     Abstract available


  38. VAN BERGE HENEGOUWEN JM, Jebbink M, Hoes LR, van der Wijngaart H, et al
    Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer.
    Eur J Cancer. 2022;171:114-123.
    PubMed     Abstract available


  39. ALTUNDAG K
    Re: Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study: Higher visceral tumour burden and weak estrogen rece
    Eur J Cancer. 2022;171:43.
    PubMed    


  40. HEIMOVAARA JH, Boere IA, de Haan J, van Calsteren K, et al
    Ten-year experience of a national multidisciplinary tumour board for cancer and pregnancy in the Netherlands.
    Eur J Cancer. 2022;171:13-21.
    PubMed     Abstract available


  41. SALGADO R, Fineberg S, De Caluwe A, de Azambuja E, et al
    Tumour infiltrating lymphocytes and ductal carcinoma in situ: The art of thinking counterintuitively.
    Eur J Cancer. 2022;168:138-140.
    PubMed    


  42. SCHIZA A, Thurfjell V, Stenmark Tullberg A, Olofsson H, et al
    Tumour-infiltrating lymphocytes add prognostic information for patients with low-risk DCIS: findings from the SweDCIS randomised radiotherapy trial.
    Eur J Cancer. 2022;168:128-137.
    PubMed     Abstract available


    May 2022
  43. AMANT F, Nekljudova V, Maggen C, Seither F, et al
    Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls.
    Eur J Cancer. 2022;170:54-63.
    PubMed     Abstract available


  44. SHAGISULTANOVA E, Gao D, Callihan E, Parris HJ, et al
    Overall survival is the lowest among young women with postpartum breast cancer.
    Eur J Cancer. 2022;168:119-127.
    PubMed     Abstract available


    April 2022
  45. MASUDA N, Ono M, Mukohara T, Yasojima H, et al
    Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort.
    Eur J Cancer. 2022;168:108-118.
    PubMed     Abstract available


  46. MARTIN M, Zielinski C, Ruiz-Borrego M, Carrasco E, et al
    Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.
    Eur J Cancer. 2022;168:12-24.
    PubMed     Abstract available


  47. GOKER E, Hendriks MP, van Tilburg M, Barcaru A, et al
    Treatment response and 5-year distant metastasis-free survival outcome in breast cancer patients after the use of MammaPrint and BluePrint to guide preoperative systemic treatment decisions.
    Eur J Cancer. 2022;167:92-102.
    PubMed     Abstract available


    March 2022
  48. DELALOGE S, Dureau S, D'Hondt V, Desmoulins I, et al
    Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer.
    Eur J Cancer. 2022 Mar 22. pii: S0959-8049(22)00035.
    PubMed     Abstract available


  49. GAILLARD T, Carton M, Mailliez A, Desmoulins I, et al
    Corrigendum to "De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): characteristics and prognosis" [Eur J Cancer 158 (2021) 181-188].
    Eur J Cancer. 2022 Mar 18. pii: S0959-8049(22)00119.
    PubMed    


  50. GELBER RD, Wang XV, Cole BF, Cameron D, et al
    Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY
    Eur J Cancer. 2022;166:219-228.
    PubMed     Abstract available


  51. VAN MACKELENBERGH MT, Seither F, Mobus V, O'Shaughnessy J, et al
    Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients.
    Eur J Cancer. 2022;166:185-201.
    PubMed     Abstract available


    February 2022
  52. LIU Z, Wang C, Chen X, Zhu J, et al
    Pathological response and predictive role of tumour-infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): a multicentre phase 2 trial.
    Eur J Cancer. 2022;165:157-168.
    PubMed     Abstract available


  53. WANG Y, Reulen RC, Kremer LCM, de Vathaire F, et al
    Male breast cancer after childhood cancer: Systematic review and analyses in the PanCareSurFup cohort.
    Eur J Cancer. 2022;165:27-47.
    PubMed     Abstract available


  54. DALENC F, Lusque A, De La Motte Rouge T, Pistilli B, et al
    Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study.
    Eur J Cancer. 2022;164:70-79.
    PubMed     Abstract available


  55. PECE S, Sestak I, Montani F, Tillhon M, et al
    Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy.
    Eur J Cancer. 2022;164:52-61.
    PubMed     Abstract available


  56. MALORNI L, Tyekucheva S, Hilbers FS, Ignatiadis M, et al
    Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.
    Eur J Cancer. 2022;164:39-51.
    PubMed     Abstract available


    January 2022
  57. VAN DER PLAS-KRIJGSMAN WG, Morgan JL, de Glas NA, de Boer AZ, et al
    Differences in treatment and survival of older patients with operable breast cancer between the United Kingdom and the Netherlands - A comparison of two national prospective longitudinal multi-centre cohort studies.
    Eur J Cancer. 2022;163:189-199.
    PubMed     Abstract available


  58. KARSTEN MM, Roehle R, Albers S, Pross T, et al
    Real-world reference scores for EORTC QLQ-C30 and EORTC QLQ-BR23 in early breast cancer patients.
    Eur J Cancer. 2022;163:128-139.
    PubMed     Abstract available


  59. TARANTINO P, Gandini S, Nicolo E, Trillo P, et al
    Evolution of low HER2 expression between early and advanced-stage breast cancer.
    Eur J Cancer. 2022;163:35-43.
    PubMed     Abstract available


  60. UGALDE-MORALES E, Grassmann F, Humphreys K, Li J, et al
    Interval breast cancer is associated with interferon immune response.
    Eur J Cancer. 2022;162:194-205.
    PubMed     Abstract available


    December 2021
  61. IWAMA E, Zenke Y, Sugawara S, Daga H, et al
    Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations.
    Eur J Cancer. 2021;162:99-106.
    PubMed     Abstract available


  62. PEUKER CA, Yaghobramzi S, Grunert C, Keilholz L, et al
    Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial.
    Eur J Cancer. 2021;162:45-55.
    PubMed     Abstract available


  63. ALBANELL J, Martinez MT, Ramos M, O'Connor M, et al
    Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER).
    Eur J Cancer. 2021;161:26-37.
    PubMed     Abstract available


  64. JUAN Z, Chen J, Ding B, Yongping L, et al
    Probiotic supplement attenuates chemotherapy-related cognitive impairment in patients with breast cancer: a randomised, double-blind, and placebo-controlled trial.
    Eur J Cancer. 2021;161:10-22.
    PubMed     Abstract available


  65. GOLATTA M, Pfob A, Busch C, Bruckner T, et al
    The potential of combined shear wave and strain elastography to reduce unnecessary biopsies in breast cancer diagnostics - An international, multicentre trial.
    Eur J Cancer. 2021;161:1-9.
    PubMed     Abstract available


    November 2021
  66. PATSOURIS A, Diop K, Tredan O, Nenciu D, et al
    Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation.
    Eur J Cancer. 2021;159:283-295.
    PubMed     Abstract available


  67. CORTI C, Giachetti PPMB, Eggermont AMM, Delaloge S, et al
    Therapeutic vaccines for breast cancer: Has the time finally come?
    Eur J Cancer. 2021 Nov 22. pii: S0959-8049(21)01185.
    PubMed     Abstract available


  68. SCHNEEWEISS A, Michel LL, Mobus V, Tesch H, et al
    Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast
    Eur J Cancer. 2021 Nov 17. pii: S0959-8049(21)01164.
    PubMed     Abstract available


  69. HANNOUN-LEVI JM, Gutierrez C, Polgar C, Strnad V, et al
    Letter comments on: The impact of isolated local recurrence on long-term outcome in early-breast cancer patients after breast-conserving therapy.
    Eur J Cancer. 2021;159:224-226.
    PubMed    


  70. VICIER C, Sfumato P, Isambert N, Dalenc F, et al
    TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients.
    Eur J Cancer. 2021;159:205-214.
    PubMed     Abstract available


    October 2021
  71. GAILLARD T, Carton M, Mailliez A, Desmoulins I, et al
    De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosis.
    Eur J Cancer. 2021;158:181-188.
    PubMed     Abstract available


  72. CAMPONE M, Bachelot T, Treilleux I, Pistilli B, et al
    A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial).
    Eur J Cancer. 2021;158:169-180.
    PubMed     Abstract available


  73. GARREFFA E, Hamad A, O'Sullivan CC, Hazim AZ, et al
    Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care.
    Eur J Cancer. 2021;159:38-51.
    PubMed     Abstract available


    September 2021
  74. HAN MG, Jang BS, Kang MH, Na D, et al
    PI3Kgammadelta inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
    Eur J Cancer. 2021;157:450-463.
    PubMed     Abstract available


  75. DAVEY MG, Richard V, Lowery AJ, Kerin MJ, et al
    OncotypeDX(c) Recurrence Score in BRCA mutation carriers: a systematic review and meta-analysis.
    Eur J Cancer. 2021;154:209-216.
    PubMed     Abstract available


  76. GUARNERI V, Giorgi CA, Cinieri S, Bengala C, et al
    Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial.
    Eur J Cancer. 2021;154:21-29.
    PubMed     Abstract available


  77. HEIN A, Hartkopf AD, Emons J, Lux MP, et al
    Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status.
    Eur J Cancer. 2021;155:1-12.
    PubMed     Abstract available


    May 2021
  78. SAESEN R, Lacombe D, Huys I
    Design, organisation and impact of treatment optimisation studies in breast, lung and colorectal cancer: The experience of the European Organisation for Research and Treatment of Cancer.
    Eur J Cancer. 2021;151:221-232.
    PubMed     Abstract available


  79. MORENO-ASPITIA A, Holmes EM, Jackisch C, de Azambuja E, et al
    Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D).
    Eur J Cancer. 2021;148:287-296.
    PubMed     Abstract available


  80. CAMPANALE A, Di Napoli A, Ventimiglia M, Pileri S, et al
    Chest wall infiltration is a critical prognostic factor in breast implant-associated anaplastic large-cell lymphoma affected patients.
    Eur J Cancer. 2021;148:277-286.
    PubMed     Abstract available


  81. VOS H, Lambein K, Wildiers H, Punie K, et al
    Immune-related adverse events after a single dose of pembrolizumab.
    Eur J Cancer. 2021;148:92-94.
    PubMed    


    March 2021
  82. PUJOL P, Barberis M, Beer P, Friedman E, et al
    Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
    Eur J Cancer. 2021;146:30-47.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: